Nab-paclitaxel

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
US
  • Adenocarcinoma of the Pancreas ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Product first approved 2005Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (83)
Breast Cancer
NCT07057427 · Henan Cancer Hospital
2025-06-24 – 2029-06-30 · Breast Cancer
What this study did
NCT04137653 · Shengjing Hospital
2021-07-19 – 2026-11-30 · Breast Cancer
What this study did
NCT04085276 · Shanghai Junshi Bioscience Co., Ltd.
2018-12-21 – 2025-02-28 · Triple-Negative Breast Cancer
What this study did
NCT04547907 · Henan Cancer Hospital
2020-09-18 – 2024-12-31 · Breast Cancer,HER2-positive
What this study did
NCT04148911 · Hoffmann-La Roche
2019-12-10 – 2024-12-15 · Triple-Negative Breast Cancer
What this study did
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
NCT02620280 · Fondazione Michelangelo
2016-04 – 2024-01-07 · Invasive Ductal Breast Carcinoma
What this study did
NCT01822314 · Fondazione Michelangelo
2013-04 – 2023-03 · Breast Cancer
What this study did
NCT02514681 · Japan Breast Cancer Research Group
2015-08-01 – 2022-08-10 · HER2-positive Locally Advanced or Metastatic Breast Cancer
What this study did
NCT03777579 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2018-12-21 – 2020-07-30 · Triple Negative Breast Cancer
What this study did
NCT01690702 · GBG Forschungs GmbH
2012-09 – 2020-07-20 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04895358 · Merck Sharp & Dohme LLC
2021-06-18 – 2027-12-18 · Breast Neoplasms
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT01583426 · GBG Forschungs GmbH
2012-07 – 2018-12 · Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer
What this study did
NCT00046527 · Celgene Corporation
started 2001-06 · Breast Neoplasms, Metastases, Neoplasm
What this study did
Non-Small Cell Lung Cancer
NCT06096844 · National Cancer Institute (NCI)
2024-07-19 – 2039-04-01 · Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT07863999 · Shanghai Pulmonary Hospital, Shanghai, China
2026-05-01 – 2033-12-01 · Locally Advanced Non-Small Cell Lung Cancer
What this study did
NCT07877584 · German Cancer Research Center
2026-11-30 – 2033-11-30 · Non-Small Cell Lung Cancer
What this study did
NCT06422143 · Merck Sharp & Dohme LLC
2024-06-10 – 2031-08-15 · Non-small Cell Lung Cancer, NSCLC
What this study did
NCT05429463 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-12-08 – 2030-08-01 · Squamous Cell Non-small Cell Lung Cancer
What this study did
NCT07524257 · ImmunityBio, Inc.
2026-05-29 – 2029-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
What this study did
NCT05502237 · Gilead Sciences
2022-10-12 – 2029-01 · Non-small Cell Lung Cancer
What this study did
NCT05722015 · Merck Sharp & Dohme LLC
2023-02-14 – 2028-05-22 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT03164616 · AstraZeneca
2017-06-01 – 2027-11-15 · Non Small Cell Lung Cancer NSCLC
What this study did
NCT04205812 · Incyte Corporation
2020-09-11 – 2026-05-28 · Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
NCT05493501 · EQRx International, Inc.
2022-12-14 – 2023-08-31 · NSCLC
What this study did
NCT03594747 · BeiGene
2018-07-30 – 2023-04-28 · Non-Small Cell Lung Cancer
What this study did
NCT02367781 · Hoffmann-La Roche
2015-04-16 – 2021-01-18 · Carcinoma, Non-Squamous Non-Small Cell Lung
What this study did
NCT03262948 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2017-12-01 – 2020-10-01 · Non-small Cell Lung Cancer
What this study did
NCT02027428 · Celgene
2014-02-11 – 2019-08-01 · Squamous Cell Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT06714604 · Sahlgrenska University Hospital
2023-10-18 – 2033-12-31 · Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy, Surgery, Pancreatectomy
What this study did
NCT07371611 · Qunxing Li,MD
2026-01-01 – 2033-12-31 · Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)
What this study did
NCT07827872 · caohaotian
2026-10-01 – 2032-10-01 · Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
What this study did
NCT07629817 · Henan Cancer Hospital
2026-06-16 – 2032-03-15 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06998940 · SWOG Cancer Research Network
2026-05-13 – 2030-12 · Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT05582265 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-10-28 – 2030-10 · Head and Neck Squamous Cell Carcinomas
What this study did
NCT06647563 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2024-11-01 – 2030-09-30 · Squamous Cell Carcinoma of Head and Neck
What this study did
Phase 2/3 (22)
Breast Cancer
NCT04907344 · Tianjin Medical University Cancer Institute and Hospital
2021-06-15 – 2025-06-30 · Triple Negative Breast Cancer
What this study did
NCT05555706 · Shanghai Jiaolian Drug Research and Development Co., Ltd
2022-12-06 – 2024-09-30 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT00397761 · Medstar Health Research Institute
started 2006-07 · Breast Cancer
What this study did
NCT01881230 · Celgene
2013-09-26 – 2016-10-28 · Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer, HER2- Negative Breast Cancer, Progesterone Receptor- Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer, Triple-negative Metastatic Breast Cancer, Metastatic Breast Cancer
What this study did
NCT01204437 · GBG Forschungs GmbH
2009-03 – 2014-01 · Breast Cancer
What this study did
NCT01647672 · Tianjin Medical University
2012-01 – 2013-12 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07410169 · Guangdong Provincial People's Hospital
2026-09-29 – 2027-12-31 · Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Paclitaxel-induced Peripheral Neuropathy
What this study did
Non-Small Cell Lung Cancer
NCT07865910 · Shanghai Henlius Biotech
2026-11-30 – 2031-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07662395 · Sinocelltech Ltd.
2026-05-09 – 2030-01-24 · Double Blind
What this study did
Other / comorbidity
NCT07463313 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2026-03 – 2032-03 · Thymoma and Thymic Carcinoma
What this study did
NCT06783140 · University Health Network, Toronto
2025-06-10 – 2031-06-02 · Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation
What this study did
NCT06861777 · YIN LI
2025-03 – 2031-05 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06288373 · Tongji Hospital
2024-04-22 – 2031-03-01 · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
What this study did
NCT06662877 · Sun Yat-sen University
2024-11-25 – 2029-09-01 · Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
What this study did
NCT06214572 · Tata Memorial Centre
2024-03-07 – 2029-07-21 · Gall Bladder Cancer
What this study did
NCT06037980 · Gruppo Oncologico del Nord-Ovest
2023-11-07 – 2029-01 · Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT06361888 · Hutchmed
2024-05-08 – 2028-05-31 · Metastatic Pancreatic Cancer
What this study did
NCT06115499 · Alliance for Clinical Trials in Oncology
2024-08-13 – 2028-01-01 · Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04060472 · Dong Wang
2019-08-20 – 2023-10-20 · Advanced Hepatobiliary and Malignant Tumors
What this study did
NCT04435652 · Qilu Pharmaceutical Co., Ltd.
2020-07-01 – 2022-11-30 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (622)
Breast Cancer
NCT04266249 · ECOG-ACRIN Cancer Research Group
2020-03-13 – 2038-12-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
What this study did
NCT06439693 · Dana-Farber Cancer Institute
2024-08-08 – 2033-03-30 · Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
What this study did
NCT06973525 · Hebei Medical University Fourth Hospital
2025-09-01 – 2032-05-31 · HER2-positive Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06964906 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-04 – 2030-12-31 · ER+/HER2- Breast Cancer
What this study did
NCT06404736 · Fudan University
2024-05-07 – 2030-11-07 · Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
What this study did
NCT06404463 · Fudan University
2024-05-06 – 2030-11-06 · Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
What this study did
NCT07527806 · Peking University Cancer Hospital & Institute
2026-05-01 – 2029-12-31 · Breast Cancer
What this study did
NCT05582538 · IFOM ETS - The AIRC Institute of Molecular Oncology
2022-12-15 – 2029-12 · Triple Negative Breast Cancer Metastatic
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07752550 · Harbin Medical University
2026-07-30 – 2029-07-30 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT05761470 · Ying Lin
2022-05-06 – 2028-12-31 · Her-2 Negative Breast Cancer, HRR Gene Mutation
What this study did
NCT06786026 · Fudan University
2024-10-09 – 2028-12-31 · TNBC, Triple Negative Breast Cancer
What this study did
NCT06849492 · Fudan University
2025-04-01 – 2028-12-31 · Advanced Triple Negative Breast Cancer
What this study did
NCT06165900 · Shengjing Hospital
2023-09-26 – 2028-12-15 · Stereotactic Radiotherapy, Immunotherapy, Breast Cancer
What this study did
NCT04159142 · Hebei Medical University Fourth Hospital
2019-11-20 – 2028-09-20 · Triple Negative Breast Cancer, Nab-paclitaxel
What this study did
NCT04138719 · Hebei Medical University Fourth Hospital
2019-11-20 – 2028-06-20 · Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
What this study did
NCT06975475 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-01 – 2028-06-01 · Breast Cancer
What this study did
NCT06441890 · University of Illinois at Chicago
2024-12-05 – 2028-06 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT06492759 · Emory University
2025-10-22 – 2028-02-13 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT06802757 · Shandong Cancer Hospital and Institute
2025-04-30 – 2028-02-01 · Breast Cancer
What this study did
NCT04398914 · Shanghai Jiao Tong University School of Medicine
2020-05-30 – 2027-12-30 · Breast Cancer Invasive
What this study did
NCT05192798 · The First Affiliated Hospital of Bengbu Medical University
2022-01-14 – 2027-12-01 · Triple-negative Breast Cancer
What this study did
NCT05227664 · Akeso
2022-03-23 – 2027-06-30 · Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer
What this study did
NCT06538896 · Zhejiang Cancer Hospital
2024-08-20 – 2027-05 · Triple-negative Breast Cancer, Bone Metastases
What this study did
NCT06632405 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-04-01 – 2027-03-31 · Breast Cancer
What this study did
NCT05447702 · West China Hospital
2022-11-01 – 2026-12-31 · Triple Negative Breast Cancer
What this study did
NCT06500208 · Shanghai Jiao Tong University School of Medicine
2024-11-01 – 2026-12-31 · Breast Cancer
What this study did
NCT07394387 · The First Affiliated Hospital with Nanjing Medical University
2025-01-01 – 2026-12-31 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT03606967 · National Cancer Institute (NCI)
2021-04-13 – 2026-12-30 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT01525966 · City of Hope Medical Center
2012-03-01 – 2026-11-11 · Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer, Stage IIB Breast Cancer, Estrogen Receptor Negative, Progesterone Receptor Negative, HER2/Neu Negative
What this study did
NCT07827079 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2024-10-01 – 2026-07-01 · Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy
What this study did
NCT04659499 · Peking Union Medical College Hospital
2021-01-01 – 2026-05-15 · Early Breast Cancer
What this study did
NCT01730833 · City of Hope Medical Center
2013-07-25 – 2026-04-20 · HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
What this study did
NCT04877821 · Guangdong Provincial People's Hospital
2021-09-15 – 2026-03-10 · Triple Negative Breast Cancer
What this study did
NCT04418154 · Fudan University
2020-06-09 – 2025-12-31 · Triple Negative Breast Cancer
What this study did
NCT05728268 · Shantou Central Hospital
2021-08-01 – 2025-12-30 · Breast Cancer
What this study did
NCT04900311 · Tianjin Medical University Cancer Institute and Hospital
2021-05 – 2025-12 · HER2+ Early or Locally Advanced Breast Cancer
What this study did
NCT04216472 · M.D. Anderson Cancer Center
2020-07-10 – 2025-09-22 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT02530489 · M.D. Anderson Cancer Center
2016-02-04 – 2025-05-23 · Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT05174832 · Fudan University
2022-09-07 – 2025-03-01 · Triple Negative Breast Cancer
What this study did
NCT04395989 · Fudan University
2020-07-28 – 2024-12-31 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT05491694 · The First Affiliated Hospital with Nanjing Medical University
2022-09-01 – 2024-12-30 · Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT03959397 · Jilin University
2019-06-01 – 2024-12-01 · Breast Cancer Stage
What this study did
Phase 1/2 (188)
Breast Cancer
NCT05981014 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-05-31 · Breast Neoplasms
What this study did
NCT07281976 · Nanjing Leads Biolabs Co.,Ltd
2026-01-27 – 2027-12-31 · Triple Negative Breast Cancer
What this study did
NCT05019690 · Fujian Cancer Hospital
2021-10-01 – 2025-06-01 · Advanced Triple Negative Breast Cancer
What this study did
NCT05253053 · TransThera Sciences (Nanjing), Inc.
2022-04-13 – 2024-08-31 · Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
What this study did
NCT04742959 · TransThera Sciences (Nanjing), Inc.
2021-03-14 – 2024-02-20 · Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
What this study did
NCT04213898 · Henan Cancer Hospital
2020-01 – 2023-01 · Triple-negative Breast Cancer
What this study did
NCT03805399 · Fudan University
2018-10-18 – 2022-12-01 · Triple-negative Breast Cancer
What this study did
NCT03872791 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2019-05-30 – 2022-10-27 · Triple-negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05981001 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-08-01 – 2035-04-30 · Breast Neoplasms
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd.
2026-07-28 – 2030-08-01 · Breast Cancer (Locally Advanced or Metastatic)
What this study did
NCT03950570 · Orinove, Inc.
2019-05-25 – 2023-01-30 · Advanced Solid Tumor, Metastatic Breast Cancer
What this study did
NCT04826016 · MedSIR
2022-03-16 – 2022-03-16 · Advanced Breast Cancer
What this study did
NCT02379247 · Priyanka Sharma
2015-02 – 2022-03 · Breast Cancer
What this study did
NCT03994107 · Peking Union Medical College
2019-10-01 – 2021-01-01 · Breast Cancer
What this study did
NCT02331251 · Western Regional Medical Center
2014-12 – 2018-01 · Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
What this study did
NCT01938833 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2014-04 – 2016-12-08 · HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00748553 · University of Utah
2008-09 – 2015-10 · Advanced or Metastatic Solid Tumors, Advanced or Metastatic Breast Cancer
What this study did
NCT00934895 · Rutgers, The State University of New Jersey
2009-07-15 – 2015-08-12 · Breast Cancer
What this study did
NCT00470548 · University of California, Davis
2007-04 – 2014-10 · Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00442260 · West Virginia University
2007-02 – 2008-10 · Metastatic Breast Cancer
What this study did
NCT00140140 · Celgene
2005-08 – 2008-02 · Stage IV (Metastatic) Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT04198766 · Inhibrx Biosciences, Inc
2019-12-10 – 2033-07 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT07563738 · Orion Corporation, Orion Pharma
2026-03-27 – 2029-09 · Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT07020221 · Verastem, Inc.
2025-06-24 – 2028-12 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
What this study did
NCT07223047 · Bristol-Myers Squibb
2025-11-25 – 2028-10-13 · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT05431270 · Phanes Therapeutics
2022-08-11 – 2028-08 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT05585320 · Immuneering Corporation
2022-10-31 – 2028-06 · Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06922591 · Tango Therapeutics, Inc.
2025-05-31 – 2027-12 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT04083599 · Genmab
2019-09-17 – 2027-01 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT04731467 · Famewave Ltd.
2021-03-19 – 2024-09-30 · Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
What this study did
NCT05383482 · Laekna Limited
2022-07-01 – 2024-07-18 · Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03267316 · Cantargia AB
2017-09-19 – 2024-03-14 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
What this study did
NCT04068896 · NGM Biopharmaceuticals, Inc
2019-10-16 – 2024-01-08 · Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
What this study did
NCT03361319 · Royal Marsden NHS Foundation Trust
2020-07 – 2023-07 · NSCLC, Recurrent, Adenocarcinoma of Lung
What this study did
NCT04430933 · NextCure, Inc.
2021-12-06 – 2022-10-30 · Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
What this study did
NCT03138889 · Nektar Therapeutics
2017-06-09 – 2022-08-24 · Non-Small Cell Lung Cancer
What this study did
NCT03840915 · EMD Serono Research & Development Institute, Inc.
2019-04-02 – 2022-07-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02382406 · Nisha Mohindra, MD
2015-06-04 – 2022-04-14 · Non-Small Cell Lung Cancer
What this study did
NCT02733250 · Centre hospitalier de l'Université de Montréal (CHUM)
2017-03-13 – 2019-12-13 · Lung Cancer
What this study did
NCT01757288 · University of Texas Southwestern Medical Center
2013-03-25 – 2019-06-03 · STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
What this study did
NCT00544648 · Vanderbilt-Ingram Cancer Center
2007-11 – 2014-04 · Lung Cancer
What this study did
NCT00077246 · Memorial Sloan Kettering Cancer Center
2003-09 – 2008-10 · Lung Cancer
What this study did
NCT00073723 · Celgene Corporation
2003-12 – 2007-01 · Non-Small Cell Lung Cancer
What this study did
Phase 1 (213)
Breast Cancer
NCT06121570 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-11-01 – 2031-08-31 · Breast Neoplasms
What this study did
NCT07178171 · Xijing Hospital
2025-11-06 – 2030-08-01 · TNBC, Triple Negative Breast Cancer
What this study did
NCT05422794 · National Cancer Institute (NCI)
2023-05-18 – 2027-03-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT05390710 · Laekna Limited
2021-06-12 – 2023-12-11 · Solid Tumor, TNBC - Triple-Negative Breast Cancer
What this study did
NCT05251766 · Xuli Meng
2022-04-20 – 2023-06-30 · Breast Cancer, Chemotherapy Effect
What this study did
NCT04584112 · Hoffmann-La Roche
2020-09-28 – 2023-03-08 · Triple-Negative Breast Cancer
What this study did
NCT04249167 · Mayo Clinic
2020-01-23 – 2021-11-17 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03719326 · Arcus Biosciences, Inc.
2018-10-15 – 2021-07-02 · TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
What this study did
NCT02073916 · Jenny C. Chang, MD
2013-10 – 2018-12 · Metastatic Breast Cancer
What this study did
NCT01090128 · University of Utah
2008-09 – 2017-03-24 · Stages II-III Breast Cancer
What this study did
NCT00331630 · Northwestern University
2006-05-04 – 2010-08-05 · Breast Cancer
What this study did
NCT00107094 · Celgene Corporation
started 2005-03 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05092373 · M.D. Anderson Cancer Center
2022-04-29 – 2026-09-01 · Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT07096869 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2025-06-26 – 2026-02-25 · Bioequivalence
What this study did
NCT02999477 · Adrienne G. Waks
2017-02-23 – 2026-01-08 · Breast Cancer
What this study did
NCT03554044 · University of California, San Francisco
2020-02-05 – 2023-12-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
What this study did
NCT02009449 · Eli Lilly and Company
2013-11-15 – 2023-07-22 · Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
What this study did
NCT04247126 · Syros Pharmaceuticals
2020-01-23 – 2023-03-30 · Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
What this study did
NCT05274893 · CSPC Ouyi Pharmaceutical Co., Ltd.
2022-03-31 – 2022-10-30 · Advanced Breast Cancer
What this study did
NCT04132817 · Bristol-Myers Squibb
2020-09-22 – 2022-08-15 · Breast Cancer
What this study did
NCT03166085 · Memorial Sloan Kettering Cancer Center
2017-05-23 – 2021-12-14 · Metastatic Breast Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02632071 · Columbia University
2016-03-01 – 2020-09-30 · Metastatic Breast Cancer, Breast Carcinoma
What this study did
NCT03304210 · University Hospital, Ghent
2017-09-16 – 2020-05-06 · Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Breast Cancer Stage IV, Stomach Cancer Stage III, Stomach Cancer Stage IV With Metastases, Pancreas Cancer, Stage III, Pancreas Cancer, Stage IV
What this study did
NCT03505528 · EpiAxis Therapeutics
2017-08-17 – 2019-10-30 · Metastatic Breast Cancer
What this study did
NCT01803282 · Gilead Sciences
2013-03-29 – 2019-04-23 · Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
What this study did
NCT01493310 · University of Chicago
2011-11 – 2018-05 · Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01929941 · Incyte Corporation
2013-09 – 2014-08 · Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
What this study did
NCT00983424 · Northwestern University
2010-02 – 2013-05 · Metastatic Breast Cancer
What this study did
NCT00637897 · Wake Forest University Health Sciences
2008-03 – 2013-03 · Breast Cancer
What this study did
NCT00004074 · National Cancer Institute (NCI)
1999-08 – 2009-02 · Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
What this study did
Non-Small Cell Lung Cancer
NCT05919537 · Hummingbird Bioscience
2023-09-06 – 2031-03-01 · Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT06607185 · Eli Lilly and Company
2024-10-21 – 2030-01 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT07699757 · Haisco Pharmaceutical Group Co., Ltd.
2026-07 – 2029-11 · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
What this study did
NCT06917079 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2025-03-31 – 2029-09 · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
What this study did
NCT07458347 · Kestrel Therapeutics, Inc.
2026-04-21 – 2029-04 · KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
What this study did
NCT06586515 · Eli Lilly and Company
2024-09-12 – 2028-03 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT06561685 · Eli Lilly and Company
2024-09-19 – 2027-10 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
What this study did
NCT04999761 · Taiho Pharmaceutical Co., Ltd.
2021-06-01 – 2027-06 · Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer, Head and Neck Cancer, Biliary Tract Cancer
What this study did
NCT03893955 · AbbVie
2019-05-21 – 2027-03 · Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
What this study did
NCT02495896 · University of Southern California
2015-09-03 – 2026-12-31 · Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
What this study did
NCT06447662 · Pfizer
2024-06-27 – 2026-10-09 · Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT06704724 · Pfizer
2024-12-10 – 2026-05-12 · Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
Phase 4 (17)
Breast Cancer
NCT05420454 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT05420467 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT04136782 · Shengjing Hospital
2021-07-19 – 2026-11-30 · Breast Cancer
What this study did
NCT05291910 · Chinese Academy of Medical Sciences
2022-03-12 – 2025-12-31 · Breast Cancer
What this study did
NCT04182568 · Xijing Hospital
2019-08-21 – 2022-08-21 · Breast Cancer
What this study did
NCT03799679 · Fudan University
2018-11-26 – 2020-02-01 · Triple Negative Breast Cancer
What this study did
NCT03799692 · Fudan University
2018-11-19 – 2019-07-30 · HER-2 Negative Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05689671 · Nikolaj Frost MD
2023-12-06 – 2026-10 · Non-Small Cell Lung Cancer Metastatic
What this study did
NCT06357598 · The Affiliated Hospital of Qingdao University
2024-01-18 – 2025-12-31 · Non-small-cell Lung Cancer (NSCLC)
What this study did
NCT02151149 · Celgene
2014-06-09 – 2017-07-14 · Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
What this study did
Other / comorbidity
NCT06388135 · Yang Jianjun, PhD
2024-05-01 – 2027-05 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05035147 · Tianjin Medical University Cancer Institute and Hospital
2021-03-25 – 2026-12 · Pancreatic Cancer
What this study did
NCT04480268 · IRCCS San Raffaele
2020-07-08 – 2026-01-01 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT06169410 · Yang Jianjun, PhD
2023-12-30 – 2025-12-31 · Advanced Gastric Cancer
What this study did
NCT04766827 · Tianjin Medical University Cancer Institute and Hospital
2020-12-12 – 2021-12 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT02812992 · AIO-Studien-gGmbH
2016-06 – 2021-02 · Adenocarcinoma Pancreas
What this study did
NCT03401827 · Seoul National University Hospital
2018-03-01 – 2019-01-01 · Pancreatic Adenocarcinoma, Chemotherapy Effect
What this study did
Early phase / not applicable (29)
Breast Cancer
NCT05287308 · Chinese Academy of Medical Sciences
2022-03 – 2027-09 · Breast Cancer
What this study did
NCT06975644 · Zhejiang Provincial People's Hospital
2025-09-01 – 2026-12-31 · Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects
What this study did
NCT06636591 · Fudan University
2024-12-23 – 2026-06-30 · Breast Cancer Female, HER2-negative Breast Cancer
What this study did
NCT04067102 · Hebei Medical University Fourth Hospital
2019-05-10 – 2026-05 · Triple Negative Breast Cancer
What this study did
NCT03647280 · Zhejiang Cancer Hospital
2018-12-01 – 2020-09-30 · Breast Cancer
What this study did
NCT03647514 · Zhejiang Cancer Hospital
2018-12-01 – 2020-09-30 · Breast Cancer
What this study did
NCT00308178 · Harold J. Burstein, MD, PhD
2006-03 – 2008-06 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06496724 · JIANG LONGWEI
2024-06-01 – 2025-07-01 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07538193 · Tang-Du Hospital
2026-05 – 2029-12 · Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
What this study did
NCT05407155 · Fudan University
2022-06-09 – 2026-08-30 · Non-small Cell Lung Cancer Metastatic
What this study did
Other / comorbidity
NCT07839676 · Fernando Pessoa Canarias University
2027-03-31 – 2032-03-31 · Borderline and Locally Advanced Pancreatic Cancer
What this study did
NCT07928362 · Ruijin Hospital
2026-10-28 – 2029-08-30 · Pancreatic Neoplasms, Neoplasm Metastasis
What this study did
NCT07139587 · Qingxia Li
2025-09 – 2028-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07855757 · Zhejiang Cancer Hospital
2026-06-01 – 2028-06-30 · Gastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, Malignant
What this study did
NCT04894643 · EBG MedAustron GmbH
2020-09-14 – 2027-12-31 · Pancreatic Cancer, Proton Therapy
What this study did
NCT02921022 · Memorial Sloan Kettering Cancer Center
2016-10 – 2027-10 · Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
What this study did
NCT06853678 · Tianjin Medical University Cancer Institute and Hospital
2025-02-28 – 2027-03-01 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT05653817 · First Affiliated Hospital Xi'an Jiaotong University
2023-01-31 – 2026-01-31 · Cholangiocarcinoma
What this study did
NCT04675866 · Henan Cancer Hospital
2020-08-17 – 2023-12-31 · Advanced Gastric Adenocarcinoma
What this study did
NCT04443036 · China Medical University, China
2020-06-11 – 2023-12-30 · Gastric Carcinoma
What this study did
NCT00499291 · Eastern Cooperative Oncology Group
started 2006-09 · Cancer
What this study did
NCT02318095 · Duke University
2015-02-17 – 2022-11-14 · Resectable Pancreatic Cancers
What this study did
NCT04518800 · Chinese PLA General Hospital
2020-08-18 – 2022-02-18 · PEG-rhG-CSF, Pancreatic Cancer
What this study did
NCT03076216 · OncoSil Medical Limited
2017-08-01 – 2020-11-28 · Unresectable Locally Advanced Pancreatic Carcinoma
What this study did
NCT03003078 · OncoSil Medical Limited
2017-03-27 – 2020-07-31 · Unresectable Locally Advanced Pancreatic Carcinoma
What this study did
NCT04017377 · Peking University Third Hospital
2019-09-01 – 2020-07-15 · Cervical Cancer
What this study did
NCT01698710 · Massachusetts General Hospital
2012-11 – 2014-09 · Pancreatic Cysts
What this study did
NCT01442974 · Grupo Hospital de Madrid
2011-01 – 2012-06 · Pancreatic Cancer
What this study did
Used as active comparator (50)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (30)
Breast Cancer
NCT07879911 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-11-30 – 2029-05-30 · Triple Negative Breast Cancer
What this study did
NCT06279364 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-02-28 – 2028-12 · Triple Negative Breast Cancer
What this study did
NCT05382299 · Gilead Sciences
2022-07-20 – 2028-07 · Triple Negative Breast Cancer, PD-L1 Negative
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07060807 · Merck Sharp & Dohme LLC
2025-07-21 – 2033-07-14 · Breast Neoplasms
What this study did
NCT07071337 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2025-07-18 – 2031-02 · Metastatic Breast Cancer
What this study did
NCT06018337 · DualityBio Inc.
2024-01-18 – 2028-08 · Metastatic Breast Cancer
What this study did
NCT05814354 · Jiangsu HengRui Medicine Co., Ltd.
2023-06-30 – 2028-06-30 · Breast Cancer
What this study did
NCT05840211 · Gilead Sciences
2023-05-08 – 2028-04 · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
What this study did
NCT04494425 · AstraZeneca
2020-07-24 – 2026-06-19 · Advanced or Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT04222972 · Hoffmann-La Roche
2020-07-24 – 2025-01-27 · RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue
What this study did
Other / comorbidity
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT06958328 · NRG Oncology
2025-08-21 – 2030-10-21 · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT07805954 · Revolution Medicines, Inc.
2026-08-28 – 2030-04 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
NCT07238283 · Jiangsu HengRui Medicine Co., Ltd.
2025-12-02 – 2028-12 · First-line Treatment of Metastatic Pancreatic Cancer
What this study did
NCT06250972 · Fudan University
2024-05-15 – 2028-05-01 · Pancreatic Adenocarcinoma
What this study did
NCT06132958 · Merck Sharp & Dohme LLC
2023-12-06 – 2028-01-10 · Endometrial Cancer
What this study did
NCT06625320 · Revolution Medicines, Inc.
2024-10-16 – 2027-12 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT03257033 · RenovoRx
2018-03-12 – 2027-09 · Locally Advanced Pancreatic Cancer
What this study did
NCT05751850 · Jiangsu HengRui Medicine Co., Ltd.
2023-06-13 – 2025-12-30 · First-line Treatment of Advanced Pancreatic Cancer
What this study did
NCT05178628 · Michalis Karamouzis
2022-02-10 – 2024-12-31 · Pancreatic Cancer, Thromboembolism
What this study did
Phase 2/3 (3)
Breast Cancer
Non-Small Cell Lung Cancer
NCT07662811 · Shanghai Chest Hospital
2026-06-01 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT04037241 · Sorrento Therapeutics, Inc.
2021-11-01 – 2022-01-01 · Malignant Tumor of Pancreas Metastatic to Liver
What this study did
Phase 2 (14)
Breast Cancer
NCT04745975 · Fudan University
2021-02-01 – 2023-01 · Triple Negative Breast Cancer
What this study did
NCT02685059 · GBG Forschungs GmbH
2016-06 – 2018-03 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05205200 · Fudan University
2022-06-06 – 2026-08-01 · Breast Cancer, Metastatic Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06731907 · Merck Sharp & Dohme LLC
2025-03-30 – 2032-03-12 · Non-small Cell Lung Cancer
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT04310007 · National Cancer Institute (NCI)
2020-07-13 – 2027-03-31 · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT07879469 · Tianjin Medical University Second Hospital
2026-10-20 – 2029-10-01 · Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates, Immunotherapy, Chemotherapy, Systemic Therapy
What this study did
NCT07769502 · AbbVie
2026-08-17 – 2028-09 · Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
What this study did
NCT07654530 · Tianjin Medical University Cancer Institute and Hospital
2026-04-24 – 2028-06-30 · Biliary Tract Cancers (BTC)
What this study did
NCT07040644 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-09 – 2028-06 · Triple Negative Breast Neoplasms
What this study did
NCT04151277 · Judith Dixon-Hughes
2017-11-28 – 2026-01-31 · Neoplasms Pancreatic
What this study did
NCT05047991 · CSPC Ouyi Pharmaceutical Co., Ltd.
2021-10 – 2024-11 · Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
What this study did
NCT03487016 · Ludwig-Maximilians - University of Munich
2019-02-15 – 2023-07 · Metastatic Pancreatic Cancer
What this study did
NCT03807999 · Hacettepe University
2015-02-19 – 2018-11-01 · Pancreatic Neoplasm
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT02574078 · Bristol-Myers Squibb
2015-11-23 – 2020-04-15 · Non-Small Cell Lung Cancer
What this study did
Early phase / not applicable (2)
HR+/HER2- Metastatic Breast Cancer
NCT02064829 · Sorrento Therapeutics, Inc.
2014-03 – 2015-07 · Metastatic Breast Cancer, Locally Recurrent Breast Cancer
What this study did
Other / comorbidity
NCT03443921 · The First Affiliated Hospital with Nanjing Medical University
2018-03 – 2021-03 · Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Neoadjuvant Therapy, Borderline Resectable Pancreatic Cancer
What this study did
Appears in other studies (57)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (25)
Breast Cancer
NCT07173751 · BioNTech SE
2025-10-30 – 2030-09 · Breast Neoplasms
What this study did
NCT06767527 · Akeso
2025-02-07 – 2028-12 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT06419621 · Biotheus Inc.
2024-06-11 – 2028-07 · Triple Negative Breast Cancer(TNBC)
What this study did
NCT04335006 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-14 – 2023-04-14 · Breast Cancer, Triple Negative Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05624996 · NRG Oncology
2023-07-12 – 2036-10-15 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
NCT05116462 · Innovent Biologics (Suzhou) Co. Ltd.
2024-03-15 – 2028-10-14 · Non-Small Cell Lung Cancer
What this study did
NCT04768075 · Guangdong Association of Clinical Trials
2021-05-28 – 2026-04-30 · Non-Small-Cell Lung Cancer
What this study did
NCT03976362 · Merck Sharp & Dohme LLC
2019-06-28 – 2026-01-30 · Carcinoma, Squamous Cell, Non-small-cell Lung
What this study did
Other / comorbidity
NCT07383922 · FutureGen Biopharmaceutical (Beijing) Co., Ltd
2026-02-28 – 2030-12-31 · Pancreatic Cancer
What this study did
NCT07822646 · Chinese PLA General Hospital
2026-10-12 – 2030-12-20 · Ovarian Cancer
What this study did
NCT06608927 · Arcus Biosciences, Inc.
2024-12-13 – 2030-11-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07079228 · Qilu Pharmaceutical Co., Ltd.
2025-09-08 – 2030-09 · Pancreatic Cancer
What this study did
NCT07621718 · Revolution Medicines, Inc.
2026-05-22 – 2030-04-22 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
NCT05281471 · Genelux Corporation
2022-08-31 – 2027-12 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
What this study did
NCT06017284 · Fudan University
2023-11-01 – 2026-11-30 · Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
What this study did
NCT04251533 · Novartis Pharmaceuticals
2020-06-08 – 2026-02-05 · Triple Negative Breast Neoplasms
What this study did
NCT04935359 · Novartis Pharmaceuticals
2021-09-30 – 2024-08-13 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT02101021 · Sierra Oncology LLC - a GSK company
2014-06-02 – 2017-04-10 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
Phase 2/3 (3)
Non-Small Cell Lung Cancer
NCT07365319 · Eikon Therapeutics
2026-06-15 – 2040-12-31 · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
What this study did
Other / comorbidity
NCT05254171 · Panbela Therapeutics, Inc.
2022-08-08 – 2027-01-01 · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
What this study did
Phase 2 (24)
Breast Cancer
NCT04872985 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-20 – 2028-12-31 · Breast Cancer, Hormone-receptor Positive Breast Cancer
What this study did
NCT00616967 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2008-05 – 2027-02 · Breast Cancer
What this study did
NCT02788981 · University of Chicago
2017-03-28 – 2026-08 · Breast Cancer
What this study did
NCT00777673 · University of Tennessee Cancer Institute
2008-10 – 2013-10 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT02229149 · US Oncology Research
2014-12 – 2022-01 · Breast Neoplasms, Malignant Tumor of the Breast
What this study did
Non-Small Cell Lung Cancer
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT05766800 · Shanghai Pulmonary Hospital, Shanghai, China
2023-03-14 – 2027-04-01 · Locally Advanced, Non-small Cell Lung Cancer
What this study did
NCT05014815 · BeiGene
2021-11-16 – 2024-09-04 · Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
What this study did
NCT05611879 · Beijing Tsinghua Chang Gung Hospital
2023-03-12 – 2024-04-30 · NSCLC, Stage III
What this study did
NCT02940990 · Shanghai Chest Hospital
2016-11 – 2019-12 · NSCLC, SBRT, GM-CSF
What this study did
NCT02590003 · Yale University
2015-11 – 2016-09 · Carcinoma, Non-small Cell Lung
What this study did
Other / comorbidity
NCT05083247 · Erasme University Hospital
2023-03-24 – 2030-12-31 · Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
What this study did
NCT07490002 · Changhai Hospital
2026-04-06 – 2030-11-30 · Esophageal Squamous Carcinoma
What this study did
NCT07248956 · Eye & ENT Hospital of Fudan University
2025-12-22 – 2029-12-30 · Hypopharyngeal Carcinoma
What this study did
NCT07711470 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-07-01 – 2029-07-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT07784413 · Zhejiang Cancer Hospital
2026-09-01 – 2029-07-30 · Gastric Cancer Peritoneal Metastasis (GCPM)
What this study did
NCT07258147 · Sichuan University
2026-10-31 – 2028-12-30 · Lung Cancer (SCLC)
What this study did
NCT07286253 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2025-10-28 – 2028-03-30 · Neoadjuvant Treatment for Locally Advanced Cervical Cancer
What this study did
NCT06728618 · Shanghai Zhongshan Hospital
2024-12 – 2028-03 · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma
What this study did
NCT05757336 · Lu Wang, MD, PhD
2022-12-22 – 2026-12-22 · Gallbladder Cancer, Initially Unresectable, the First Line Treatment
What this study did
NCT06261359 · Qilu Pharmaceutical Co., Ltd.
2024-03-19 – 2026-10 · Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT05042128 · Australasian Gastro-Intestinal Trials Group
2022-04-13 – 2025-10-01 · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
What this study did
NCT04815408 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-04-01 – 2025-04-01 · Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1, Neoadjuvant Immunotherapy
What this study did
NCT04089150 · Australasian Gastro-Intestinal Trials Group
2019-10-01 – 2023-08-30 · Pancreatic Cancer
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT06592664 · Lisata Therapeutics, Inc.
2030-01 – 2040-01 · Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT04460066 · Lee's Pharmaceutical Limited
2020-11-18 – 2023-07-15 · Esophageal Cancer
What this study did
NCT03086369 · Eli Lilly and Company
2017-06-22 – 2021-06-17 · Metastatic Pancreatic Cancer
What this study did
Phase 1 (1)
Breast Cancer
NCT06769425 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-07 – 2026-08-31 · Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC, Advanced Prostate Cancer, Advanced Gastric Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03690323 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2015-04-07 – 2020-05 · Locally Advanced Pancreatic Cancer
What this study did

Competitive landscape

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nab-Paclitaxel: this drugApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(271 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nab-paclitaxel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (27)
November 2026 (3)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT05429463 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT06725498 · CT.gov ↗
What to watch
Phase 2GC/GEJCRecruiting
Est. primary completion 2026-11-30 · NCT07770113 · CT.gov ↗
What to watch
December 2026 (24)
Phase 1Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy …Active not recruiting
Est. primary completion 2026-12 · NCT02207465 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2026-12 · NCT02340117 · CT.gov ↗
What to watch
Phase 2Unresectable Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12 · NCT02632305 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06538896 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12-15 · NCT07245797 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-17 · NCT06747169 · CT.gov ↗
What to watch
Phase 2Head and Neck CancerNot yet recruiting
Est. primary completion 2026-12-20 · NCT06793761 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cervical CancerRecruiting
Est. primary completion 2026-12-30 · NCT06055738 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Phase 2Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing, Tislelizumab, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07125547 · CT.gov ↗
What to watch
Phase 2Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07126119 · CT.gov ↗
What to watch
Phase 2Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor, Kidney-sparing, Nab-paclitaxelRecruiting
Est. primary completion 2026-12-30 · NCT07233252 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced Pancreatic CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03652428 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8Active not recruiting
Est. primary completion 2026-12-31 · NCT04115163 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic Cancer, Proton TherapyRecruiting
Est. primary completion 2026-12-31 · NCT04894643 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer MetastaticRecruiting
Est. primary completion 2026-12-31 · NCT05969171 · CT.gov ↗
What to watch
Phase 3GliomaRecruiting
Est. primary completion 2026-12-31 · NCT06330337 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06802757 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06808971 · CT.gov ↗
What to watch
Phase 1Peritoneal (Metastatic) CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07454031 · CT.gov ↗
What to watch
Phase 2ESCCRecruiting
Est. primary completion 2026-12-31 · NCT07808853 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07867392 · CT.gov ↗
What to watch
2027 (122)
January 2027 (6)
Phase 2Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2027-01 · NCT05827055 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-01 · NCT06741644 · CT.gov ↗
What to watch
Phase 2Advanced Pancreatic CancersRecruiting
Est. primary completion 2027-01 · NCT06770439 · CT.gov ↗
What to watch
Phase 2Advanced Urothelial Carcinoma, Probiotics, ImmunotherapyRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-01-10 · NCT06345599 · CT.gov ↗
What to watch
Phase 2TNBCEnrolling by invitation
Est. primary completion 2027-01-15 · NCT07376629 · CT.gov ↗
What to watch
February 2027 (7)
Phase 1/2Pancreatic Cancer, PDAC, Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2027-02-01 · NCT05355298 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT06770452 · CT.gov ↗
What to watch
Phase 1Pancreas CancerActive not recruiting
Est. primary completion 2027-02-02 · NCT05497778 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-02-12 · NCT06492759 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-02-25 · NCT07452601 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, Gastroesophageal-junction CancerRecruiting
Est. primary completion 2027-02-28 · NCT05687357 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8Recruiting
Est. primary completion 2027-02-28 · NCT07226856 · CT.gov ↗
What to watch
March 2027 (6)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03 · NCT03893955 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT06861894 · CT.gov ↗
What to watch
Phase 1Advanced Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT07348107 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2027-03-31 · NCT05422794 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06632405 · CT.gov ↗
What to watch
Phase 1/2Advanced Pancreatic Cancer, Ductal Adenocarcinoma of PancreasRecruiting
Est. primary completion 2027-03-31 · NCT07777211 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-04-01 · NCT07751055 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PembrolizumabRecruiting
Est. primary completion 2027-04-30 · NCT06102395 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-04-30 · NCT06349967 · CT.gov ↗
What to watch
Phase 2Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2027-04-30 · NCT07530445 · CT.gov ↗
What to watch
May 2027 (10)
Phase 2Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, CholangiocarcinomaActive not recruiting
Est. primary completion 2027-05-01 · NCT05451043 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2027-05-01 · NCT06939270 · CT.gov ↗
What to watch
Phase 2Gallbladder Cancer UnresectableEnrolling by invitation
Est. primary completion 2027-05-01 · NCT07310069 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2027-05-14 · NCT06953999 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2027-05-15 · NCT06951997 · CT.gov ↗
What to watch
Phase 2Angiosarcoma MetastaticRecruiting
Est. primary completion 2027-05-20 · NCT04859465 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT06421298 · CT.gov ↗
What to watch
Phase 2High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal CancerRecruiting
Est. primary completion 2027-05-30 · NCT07432594 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-05-30 · NCT07618910 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (13)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT04999761 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT05585320 · CT.gov ↗
What to watch
Phase 2Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT05825066 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06922591 · CT.gov ↗
What to watch
Phase 2Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-06-01 · NCT03907475 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-06-10 · NCT05420454 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-06-20 · NCT07163273 · CT.gov ↗
What to watch
Phase 1/2Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT04396821 · CT.gov ↗
What to watch
Phase 2Metastatic Head-and-neck Squamous-cell CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04831320 · CT.gov ↗
What to watch
Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2027-06-30 · NCT06182072 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT06513455 · CT.gov ↗
What to watch
Phase 2Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06-30 · NCT07668453 · CT.gov ↗
What to watch
July 2027 (9)
Phase 2Pancreatic Cancer, Metastatic AdenocarcinomaRecruiting
Est. primary completion 2027-07 · NCT05776524 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-07 · NCT06576115 · CT.gov ↗
What to watch
Phase 2Cervical CarcinomaNot yet recruiting
Est. primary completion 2027-07 · NCT07088731 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cervical CancerRecruiting
Est. primary completion 2027-07 · NCT07876154 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-07-10 · NCT05420467 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-07-10 · NCT06791148 · CT.gov ↗
What to watch
Phase 2Gastric (Stomach) CancerNot yet recruiting
Est. primary completion 2027-07-25 · NCT06748508 · CT.gov ↗
What to watch
Phase 1/2Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic …Active not recruiting
Est. primary completion 2027-07-30 · NCT07280377 · CT.gov ↗
What to watch
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-07-31 · NCT03181100 · CT.gov ↗
What to watch
August 2027 (10)
Phase 1/2Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell NeoplasmRecruiting
Est. primary completion 2027-08 · NCT06483555 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06917079 · CT.gov ↗
What to watch
Early phase / not applicableGastric Cancer, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08 · NCT07139587 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-08 · NCT07444541 · CT.gov ↗
What to watch
Phase 2Esophagus CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT07046221 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2027-08-01 · NCT07178171 · CT.gov ↗
What to watch
Phase 1/2Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the PancreasRecruiting
Est. primary completion 2027-08-01 · NCT07701486 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-10 · NCT07089199 · CT.gov ↗
What to watch
Phase 2Pancreatic Adenocarcinoma, Resectable Pancreatic CancerRecruiting
Est. primary completion 2027-08-29 · NCT05624918 · CT.gov ↗
What to watch
Phase 2Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2027-08-31 · NCT06423326 · CT.gov ↗
What to watch
September 2027 (11)
Early phase / not applicableBreast CancerNot yet recruiting
Est. primary completion 2027-09 · NCT05287308 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma, Carcinoma, Pancreatic DuctalRecruiting
Est. primary completion 2027-09 · NCT07259317 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-09 · NCT07871461 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-10 · NCT05192798 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-15 · NCT07601178 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response RateNot yet recruiting
Est. primary completion 2027-09-20 · NCT07145931 · CT.gov ↗
What to watch
Phase 2Hepatoid Adenocarcinoma of StomachRecruiting
Est. primary completion 2027-09-20 · NCT07178340 · CT.gov ↗
What to watch
Phase 1Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT06532331 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT06662669 · CT.gov ↗
What to watch
Phase 1Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-09-30 · NCT07317609 · CT.gov ↗
What to watch
October 2027 (10)
Early phase / not applicablePancreatic Cancer, Advanced Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2027-10 · NCT02921022 · CT.gov ↗
What to watch
Phase 2Pancreas Adenocarcinoma, Resectable Pancreatic CancerRecruiting
Est. primary completion 2027-10 · NCT03492671 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10 · NCT06561685 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced or Metastatic Pancreatic Cancer WithRecruiting
Est. primary completion 2027-10 · NCT07296341 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage IIINot yet recruiting
Est. primary completion 2027-10-01 · NCT05562297 · CT.gov ↗
What to watch
Phase 2Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-10-30 · NCT04940286 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT04266249 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT06604351 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT07828756 · CT.gov ↗
What to watch
November 2027 (4)
Phase 1/2Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS MutationRecruiting
Est. primary completion 2027-11 · NCT07678593 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-11-10 · NCT05881525 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-30 · NCT04297605 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Immunotherapy, PembrolizumabRecruiting
Est. primary completion 2027-11-30 · NCT07261683 · CT.gov ↗
What to watch
December 2027 (32)
Phase 2Phase II, Open-label, Parallel 2-arm, Multi-centerActive not recruiting
Est. primary completion 2027-12 · NCT05026905 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 1/2Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal CancerRecruiting
Est. primary completion 2027-12 · NCT05482893 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05582538 · CT.gov ↗
What to watch
Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2027-12 · NCT06639724 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial CancerRecruiting
Est. primary completion 2027-12 · NCT06906341 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2027-12 · NCT07255404 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2027-12 · NCT07296705 · CT.gov ↗
What to watch
Phase 1Gastric Cancer (GC)Not yet recruiting
Est. primary completion 2027-12 · NCT07923396 · CT.gov ↗
What to watch
Phase 2/3Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma …Active not recruiting
Est. primary completion 2027-12-01 · NCT06115499 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07200947 · CT.gov ↗
What to watch
Phase 2SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07307443 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2027-12-30 · NCT06177522 · CT.gov ↗
What to watch
Phase 2Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally AdvancedNot yet recruiting
Est. primary completion 2027-12-30 · NCT07018063 · CT.gov ↗
What to watch
Phase 1Adenocarcinoma PancreasRecruiting
Est. primary completion 2027-12-30 · NCT07253662 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07272109 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent GlioblastomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04528680 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-12-31 · NCT04683315 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 1Metastatic Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06229496 · CT.gov ↗
What to watch
Phase 2Cholangiocarcinoma ResectableNot yet recruiting
Est. primary completion 2027-12-31 · NCT06569225 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer (EsC)Recruiting
Est. primary completion 2027-12-31 · NCT06869213 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT06964906 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07281976 · CT.gov ↗
What to watch
Phase 2/3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07410169 · CT.gov ↗
What to watch
Phase 1/2Borderline Resectable Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07705919 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07733830 · CT.gov ↗
What to watch
Phase 2Pancreas Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT07806110 · CT.gov ↗
What to watch
Phase 2BTCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07890506 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic Neoplasms, Neoplasm MetastasisNot yet recruiting
Est. primary completion 2027-12-31 · NCT07928362 · CT.gov ↗
What to watch
2028 (54)
January 2028 (6)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruiting
Est. primary completion 2028-01-01 · NCT07547332 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2028-01-01 · NCT07595770 · CT.gov ↗
What to watch
Phase 1Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT07024615 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT07284836 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2028-01-31 · NCT07678580 · CT.gov ↗
What to watch
February 2028 (1)
Phase 1Unresectable or Metastatic Advanced Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2028-02 · NCT06393400 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03 · NCT06586515 · CT.gov ↗
What to watch
Phase 2CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT07483554 · CT.gov ↗
What to watch
April 2028 (3)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07458347 · CT.gov ↗
What to watch
Phase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …Recruiting
Est. primary completion 2028-04 · NCT07491445 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant TherapyRecruiting
Est. primary completion 2028-04-30 · NCT07601737 · CT.gov ↗
What to watch
May 2028 (4)
Phase 2Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-05 · NCT07076212 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Active not recruiting
Est. primary completion 2028-05-30 · NCT07682376 · CT.gov ↗
What to watch
Phase 2/3Metastatic Pancreatic CancerRecruiting
Est. primary completion 2028-05-31 · NCT06361888 · CT.gov ↗
What to watch
Phase 2ESCCNot yet recruiting
Est. primary completion 2028-05-31 · NCT07493993 · CT.gov ↗
What to watch
June 2028 (10)
Phase 2Pancreatic Cancer, Adenocarcinoma of the Pancreas, AdenocarcinomaActive not recruiting
Est. primary completion 2028-06 · NCT04543071 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-06 · NCT05502237 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06441890 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-15 · NCT07845786 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2028-06-22 · NCT07235202 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2028-06-29 · NCT04241276 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07057427 · CT.gov ↗
What to watch
Phase 2QL1706, ESCC, First-line TherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07533305 · CT.gov ↗
What to watch
Phase 2Gallbladder CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07767994 · CT.gov ↗
What to watch
Early phase / not applicableGastric Cancer (GC), Peritoneal Metastases From Gastric Cancer, Ascites, MalignantActive not recruiting
Est. primary completion 2028-06-30 · NCT07855757 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Pancreas AdenocarcinomaRecruiting
Est. primary completion 2028-07-01 · NCT07043270 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-07-30 · NCT07752550 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-01 · NCT05800587 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-08-30 · NCT07457346 · CT.gov ↗
What to watch
September 2028 (8)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09 · NCT07049055 · CT.gov ↗
What to watch
Phase 1/2Advan'ce'd, AdvancedNot yet recruiting
Est. primary completion 2028-09 · NCT07361991 · CT.gov ↗
What to watch
Phase 3Pancreatic Cancer, AdultRecruiting
Est. primary completion 2028-09 · NCT07436741 · CT.gov ↗
What to watch
Phase 2Malignant Neoplam, Advanced Solid TumorsRecruiting
Est. primary completion 2028-09-26 · NCT07793942 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06904378 · CT.gov ↗
What to watch
Phase 2ORR,OS,PFSNot yet recruiting
Est. primary completion 2028-09-30 · NCT07328802 · CT.gov ↗
What to watch
October 2028 (5)
Phase 3Head and Neck Squamous Cell CarcinomasRecruiting
Est. primary completion 2028-10 · NCT05582265 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10 · NCT07906587 · CT.gov ↗
What to watch
Phase 1Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum …Recruiting
Est. primary completion 2028-10-11 · NCT05285358 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)Not yet recruiting
Est. primary completion 2028-10-31 · NCT07812467 · CT.gov ↗
What to watch
December 2028 (9)
Phase 2/3Biliary Tract Cancer, CholangiocarcinomaRecruiting
Est. primary completion 2028-12 · NCT06037980 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07475234 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07864571 · CT.gov ↗
What to watch
Phase 2Head and Neck CancersNot yet recruiting
Est. primary completion 2028-12-01 · NCT06894459 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-12-31 · NCT05382559 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07610629 · CT.gov ↗
What to watch
Phase 2Late-stage Resectable Esophageal Squamous CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07622797 · CT.gov ↗
What to watch
2029 (33)
January 2029 (8)
Phase 1Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-01 · NCT07875907 · CT.gov ↗
What to watch
Phase 3Pancreatic Adenocarcinoma Advanced or MetastaticRecruiting
Est. primary completion 2029-01-01 · NCT06897644 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic CancerRecruiting
Est. primary completion 2029-01-01 · NCT07802184 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07885709 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07948317 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
Phase 1Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the PeritoneumRecruiting
Est. primary completion 2029-01-14 · NCT06675136 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Adenocarcinoma, Albumin-bound Paclitaxel (II), Gemcitabine, First-LineNot yet recruiting
Est. primary completion 2029-01-31 · NCT07831330 · CT.gov ↗
What to watch
February 2029 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
Phase 2Untreated, Advanced Pancreatic CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07578337 · CT.gov ↗
What to watch
March 2029 (3)
Phase 1Pancreatic Adenocarcinoma MetastaticRecruiting
Est. primary completion 2029-03 · NCT07377045 · CT.gov ↗
What to watch
Phase 2/3Thymoma and Thymic CarcinomaNot yet recruiting
Est. primary completion 2029-03 · NCT07463313 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-03-25 · NCT06323369 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Borderline Resectable Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04 · NCT07616362 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07699757 · CT.gov ↗
What to watch
May 2029 (4)
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07538193 · CT.gov ↗
What to watch
Phase 1/2Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic, Pancreatic Adenocarcinoma Metastatic, Adenosquamous Carcinoma of the Pancreas …Not yet recruiting
Est. primary completion 2029-05 · NCT07665684 · CT.gov ↗
What to watch
Phase 2Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2029-05 · NCT07845565 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-05-01 · NCT07527806 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Locally Advanced, ResectableActive not recruiting
Est. primary completion 2029-06-20 · NCT07374003 · CT.gov ↗
What to watch
July 2029 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch
Phase 2/3Gall Bladder CancerRecruiting
Est. primary completion 2029-07-21 · NCT06214572 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗
What to watch
September 2029 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09 · NCT07563738 · CT.gov ↗
What to watch
Phase 2/3Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase InhibitorNot yet recruiting
Est. primary completion 2029-09-01 · NCT06662877 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT04892953 · CT.gov ↗
What to watch
Phase 3Squamous Cell Carcinoma of Head and NeckNot yet recruiting
Est. primary completion 2029-09-30 · NCT06647563 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic CancerRecruiting
Est. primary completion 2029-10-01 · NCT07283705 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2Esophageal CancerRecruiting
Est. primary completion 2029-12-31 · NCT06869226 · CT.gov ↗
What to watch
Phase 3Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2029-12-31 · NCT06998940 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2029-12-31 · NCT07640295 · CT.gov ↗
What to watch
Phase 2Gastric Cancer (Diagnosis)Not yet recruiting
Est. primary completion 2029-12-31 · NCT07904442 · CT.gov ↗
What to watch
Phase 2Melanoma, Immune Checkpoint InhibitorRecruiting
Est. primary completion 2029-12-31 · NCT07934927 · CT.gov ↗
What to watch
2030 (18)
January 2030 (3)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01 · NCT06607185 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT06745882 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-24 · NCT07662395 · CT.gov ↗
What to watch
February 2030 (1)
Phase 2Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2030-02-03 · NCT07748611 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1/2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2030-04 · NCT05257993 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Pancreatic Cancer ResectableNot yet recruiting
Est. primary completion 2030-08-31 · NCT07155629 · CT.gov ↗
What to watch
September 2030 (3)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the PeritoneumActive not recruiting
Est. primary completion 2030-09-30 · NCT04858009 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2030-09-30 · NCT07096362 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-11-01 · NCT06109402 · CT.gov ↗
What to watch
December 2030 (6)
Phase 2Recurrent or Metastatic Cervical CancerNot yet recruiting
Est. primary completion 2030-12 · NCT07763496 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07865910 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2030-12-31 · NCT04589234 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2030-12-31 · NCT05981014 · CT.gov ↗
What to watch
Phase 3Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)Recruiting
Est. primary completion 2030-12-31 · NCT07371611 · CT.gov ↗
What to watch
Phase 2HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07628062 · CT.gov ↗
What to watch
2031 (8)
January 2031 (1)
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-01 · NCT07318883 · CT.gov ↗
What to watch
March 2031 (2)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-03-01 · NCT05919537 · CT.gov ↗
What to watch
Phase 2/3Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant ChemoimmunotherapyRecruiting
Est. primary completion 2031-03-01 · NCT06288373 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2/3Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2031-05 · NCT06861777 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2/3Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene MutationActive not recruiting
Est. primary completion 2031-06-02 · NCT06783140 · CT.gov ↗
What to watch
August 2031 (2)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗
What to watch
Phase 2Head & Neck CancerNot yet recruiting
Est. primary completion 2031-08-23 · NCT07752394 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12-01 · NCT06837948 · CT.gov ↗
What to watch
2032 (5)
March 2032 (2)
Phase 3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-03-15 · NCT07629817 · CT.gov ↗
What to watch
Early phase / not applicableBorderline and Locally Advanced Pancreatic CancerNot yet recruiting
Est. primary completion 2032-03-31 · NCT07839676 · CT.gov ↗
What to watch
April 2032 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-04-30 · NCT05981001 · CT.gov ↗
What to watch
October 2032 (1)
Phase 3Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral CancerNot yet recruiting
Est. primary completion 2032-10-01 · NCT07827872 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy, Surgery …Recruiting
Est. primary completion 2032-12-31 · NCT06714604 · CT.gov ↗
What to watch
2033 (3)
July 2033 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch
November 2033 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2033-11-30 · NCT07877584 · CT.gov ↗
What to watch
December 2033 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-12-01 · NCT07863999 · CT.gov ↗
What to watch
2039 (1)
April 2039 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2039-04-01 · NCT06096844 · CT.gov ↗
What to watch

See the full readout calendar ↗